A prospective three-dimensional analysis about the impact of differences in the clinical target volume in prostate cancer irradiation on normal-tissue exposure: A potential for increasing the benefit/risk ratio

Strahlentherapie und Onkologie

Volumn 181, Issue 12, 2005, Pages 789-795

  Hille, Andrea ^a   Töws, Nadja ^a   Schmidberger, Heinz ^a   Hess, Clemens F ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Clinical target volume; Normal tissue complication; Prostate cancer; Radiotherapy

Indexed keywords

ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MALE; PROSPECTIVE STUDY; PROSTATE CANCER; RADIATION DOSE; RADIATION EXPOSURE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEMINAL VESICLE; TARGET ORGAN;

DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; IMAGING, THREE-DIMENSIONAL; MALE; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIATION PROTECTION; RADIOMETRY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; RECTUM; RISK ASSESSMENT; RISK FACTORS; URINARY BLADDER;

EID: 29144499246     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-005-1452-1     Document Type: Article

References (48)

1. Boersma LJ, van den Brink M, Bruce AM, et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 GY) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys 1998;41:83-92.
2. Brabbins D, Martinez A, Yan D, et al. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity. Int J Radiat Oncol Biol Phys 2005;61:400-8.
3. Cozzarini C, Fiorino C, Ceresoli GL, et al. Significant correlation between rectal DVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6-70.2 Gy). Int J Radiat Oncol Biol Phys 2003;55:688-94.
4. Debois M, Oyen R, Maes F, et al. The contribution of magnetic resonance imaging to the three-dimensional treatment planning of localized prostate cancer. Int J Radiat Oncol Biol Phys 1999;45:857-65.
5. De Meerleer GO, Vakaet LA, De Gersem WR, et al. Radiotherapy of prostate cancer with or without intensity modulated beams: a planning comparison. Int J Radiat Oncol Biol Phys 2000;47:639-48.
6. De Meerleer G, Vakaet L, De Gersem W, et al. Direct segment aperture and weight optimization for intensity-modulated radiotherapy of prostate cancer. Strahlenther Onkol 2004;180:136-43.
7. Diaz A, Roach M 3rd, Marquez C, et al. Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 1994;30:323-9.
8. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109-22.
9. Feldmann HJ, Breul J, Zimmermann F, et al. Probability of seminal vesicle involvement in localized prostatic carcinoma. Significance in conformal radiotherapy. Strahlenther Onkol 1998;174:566-70.
10. Fiorino C, Cozzarini C, Vavassori V, et al. Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions. Radiother Oncol 2002;64:1-12.
11. Fiorino C, Reni M, Bolognesi A, et al. Intra- and inter-observer variability in contouring prostate and seminal vesicles: implications for conformal treatment planning. Radiother Oncol 1998;47:285-92.
12. Fiorino C, Sanguineti G, Cozzarini C, et al. Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys 2003;57:953-62.
13. Fiorino C, Vavassori V, Sanguineti G, et al. Rectum contouring variability in patients treated for prostate cancer: impacton rectum dose-volume histograms and normal tissue complication probability. Radiother Oncol 2002;63:249-55.
14. Foppiano F, Fiorino C, Frezza G, et al. The impact of contouring uncertainty on rectal 3D dose-volume data: results of a dummy run in a multicenter trial (AIROPROS01-02). Int J Radiat Oncol Biol Phys 2003;57:573-9.
15. Friedman AC, Seidmon EJ, Radecki PD, et al. Relative merits of MRI, transrectal endosonography and CT in diagnosis and staging of carcinoma of prostate. Urology 1988;31:530-7.
16. Geinitz H, Zimmermann FB, Narkwong L, et al. Prostatic carcinoma: problems in the interpretation of rectal dose-volume histograms. Strahlenther Onkol 2000;176:168-72.
17. Gershkevitsh E, Clark CH, Staffurth J, et al. Dose to bone marrow using IMRT techniques in prostate cancer patients. Strahlenther Onkol 2005;181:1172-8.
18. Goldner G, Wachter-Gerstner N, Wachter S, et al. Acute side effects during 3-D-planned conformal radiotherapy of prostate cancer. Differences between patient's self-reported questionnaire and the corresponding doctor's report. Strahlenther Onkol 2003;179:320-7.
19. Greco C, Mazzetta C, Cattani F, et al. Finding dose-volume constraints to reduce late rectal toxicity following 3D-conformal radiotherapy (3D-CRT) of prostate cancer. Radiother Oncol 2003;69:215-22.
20. Hanks GE, Schultheiss TE, Hanlon AL, et al. Optimization of conformal radiation treatment of prostate cancer: report of a dose escalation study. Int J Radiat Oncol Biol Phys 1997;37:543-50.
21. Hille A, Töws N, Hess CF. A comparison of three-, and four-field-techniques in different CTVs in prostate cancer irradiation using dose-volume histograms: a prospective three-dimensional analysis. Br J Radiol 2005:in press.
22. Huang EH, Pollack A, Levy L, et al. Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2002;54:1314-21.
23. International Commission on Radiation Units and Measurements. ICRU Report 50: Prescribing, recording, and reporting photon beam therapy. Washington: International Commission on Radiation Units and Measurements, 1993.
24. Katcher J, Kupelian PA, Zippe C, et al. Indications for excluding the seminal vesicles when treating clinically localized prostatic adenocarcinoma with radiotherapy alone. Int J Radiat Oncol Biol Phys 1997;37:871-6.
25. Kestin L, Goldstein N, Vicini F, et al. Treatment of prostate cancer with radiotherapy: should the entire seminal vesicles be included in the clinical target volume? Int J Radiat Oncol Biol Phys 2002;54:686-97.
26. Khoo VS, Padhani AR, Tanner SF, et al. Comparison of MRI with CT for the radiotherapy planning of prostate cancer: a feasibility study. Br J Radiol 1999;72:590-7.
27. Koelbl O, Schwab F, Bratengeier K, et al. Radiotherapy of prostate cancer with multileaf collimators (MLCs) optimization of the undulating dose distribution at the MLC edge. Strahlenther Onkol 2005;181:108-12.
28. Koper PC, Heemsbergen WD, Hoogeman MS, et al. Impact of volume and location of irradiated rectum wall on rectal blood loss after radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys 2004;58:1072-82.
29. Lebesque JV, Bruce AM, Kroes AP, et al. Variation in volumes, dose-volume histograms, and estimated normal tissue complication probabilities of rectum and bladder during conformal radiotherapy of T3 prostate cancer. Int J Radiat Oncol Biol Phys 1995;33:1109-19.
30. Li XA, Wang JZ, Jursinic PA, et al. Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2005;61:1251-7.
31. Marks LB, Anscher MS. Radiotherapy for prostate cancer: should the seminal vesicles be considered target? Int J Radiat Oncol Biol Phys 1992;24:435-40.
32. Marks LB, Carroll PR, Dugan TC, et al. The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy. Int J Radiat Oncol Biol Phys 1995;31:1257-80.
33. Pollack A, Zagars GK, Cole CJ, et al. Significance of downstaging in muscle-invasive bladder cancer treated with preoperative radiotherapy. Int J Radiat Oncol Biol Phys 1997;37:41-9.
34. Rasch C, Barillot I, Remeijer P, et al. Definition of the prostate in CT and MRI: a multi-observer study. Int J Radiat Oncol Biol Phys 1999;43:57-66.
35. Rifkin MD, Zerhouni EA, Gatsonis CA, et al. Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. N Engl J Med 1990;323:621-6.
36. Roach M 3rd. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:1923-4.
37. Sanguineti G, Castellone P, Foppiano F, et al. Anatomic variations due to radical prostatectomy. Impact on target volume definition and dose-volume parameters of rectum and bladder. Strahlenther Onkol 2004;180:563-72.
38. Sanguineti G, Franzone P, Marcenaro M, et al. Sucralfate versus mesalazine versus hydrocortisone in the prevention of acute radiation proctitis during conformal radiotherapy for prostate carcinoma. A randomized study. Strahlenther Onkol 2003;179:464-70.
39. Seddon B, Bidmead M, Wilson J, et al. Target volume definition in conformal radiotherapy for prostate cancer: quality assurance in the MRC RT-01 trial. Radiother Oncol 2000;56:73-83.
40. Smith JA Jr, Scardino PT, Resnick MI, et al. Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multi-institutional trial. J Urol 1997;157:902-6.
41. Stock RG, Stone NN, Ianuzzi C, et al. Seminal vesicle biopsy and laparoscopic pelvic lymph node dissection: implications for patient selection in the radiotherapeutic management of prostate cancer. Int J Radiat Oncol Biol Phys 1995;33:815-21.
42. Storey MR, Pollack A, Zagars G, et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 2000;48:635-42.
43. Terris MK, McNeal JE, Stamey TA. Invasion of the seminal vesicles by prostatic cancer: detection with transrectal sonography. AJR Am J Roentgenol 1990;155:811-5.
44. Valicenti RK, Sweet JW, Hauck WW, et al. Variation of clinical target volume definition in three-dimensional conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 1999;44:931-5.
45. Wachter S, Gerstner N, Goldner G, et al. Rectal sequelae after conformal radiotherapy of prostate cancer: dose-volume histograms as predictive factors. Radiother Oncol 2001;59:65-70.
46. Wachter-Gerstner N, Wachter S, Goldner G, et al. Biochemical response after 3-d conformal radiotherapy of localized prostate cancer to a total dose of 66 Gy. 4-year results. Strahlenther Onkol 2002;178:542-7.
47. Zapatero A, Garcia-Vicente F, Modolell I, et al. Impact of mean rectal dose on late rectal bleeding after conformal radiotherapy for prostate cancer: dose-volume effect. Int J Radiat Oncol Biol Phys 2004;59:1343-51.
48. Zelefsky MJ, Fuks Z, Wolfe T, et al. Locally advanced prostatic cancer: long-term toxicity outcome after three-dimensional conformal radiation therapy - a dose-escalation study. Radiology 1998;209:169-74.